翰森製藥(03692.HK)擬發行6億美元零息可換股債券
格隆匯 1 月 8日丨翰森製藥(03692.HK)發佈公吿,2021年1月7日,公司與經辦人訂立認購協議。根據認購協議,(其中包括)公司已有條件同意向經辦人(或根據經辦人指示)發行6億美元於2026年到期的零息可換股債券,而經辦人亦已有條件與公司商定個別而非共同認購和支付債券,惟須遵守認購協議所載的若干條件。
債券可依照條款和條件轉換成換股股份。假設債券按每股股份的初始換股價60.00港元悉數轉換,且公司概無進一步發行股份,債券將可轉換成7752.9萬股股份,佔公司於該公吿日期已發行股本約1.31%,並佔經債券悉數轉換時發行換股股份擴大後的公司於該公吿日期已發行股本約1.29%。
經扣除佣金及其他相關費用後,預計債券所得款項淨額約5.9565億美元,按照初始換股價計算,每股換股股份的發行價格淨額約59.57港元。公司將向聯交所申請批准債券根據上市規則第37章在聯交所上市及買賣;及批准換股股份在聯交所上市及買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.